Climb Bio, Inc. — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Climb Bio announced initial Phase 2 PrisMN data for budoprutug (anti-CD19 mAb) in primary membranous nephropathy at ASN Kidney Week 2026 (Oct 24). The 200 mg low-dose cohort demonstrated 70% mean PLA2R antibody reduction and 38% immunologic remission rate (71% in high-baseline-PLA2R subgroup) at Week 12, with 98% B-cell depletion at Week 4 in the 600 mg cohort. Budoprutug was generally well-tolerated; no serious adverse events, discontinuations, or deaths reported. Additional data from all dose cohorts expected in 2027.
Why this rating
Early Phase 2 efficacy data in ~75k-patient indication with no FDA-approved therapies. Results consistent with Phase 1b; supports dose escalation path. Material for $44.8M company; validates lead program and de-risks regulatory strategy. Positive biomarker endpoints accelerate development timeline.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.